Free tool
FAERS Monitor: Briumvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761238 or its brand name (Briumvi, Ublituximab-Xiiy). Reports on generic versions are filed under their own applications.
Reports
3,894
Serious
932
24% of reports
Hospitalization
490
Death reported
67
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infusion related reaction1,435
- fatigue238
- headache124
- malaise116
- pain109
- urinary tract infection103
- illness100
- multiple sclerosis relapse99
- asthenia94
- gait disturbance90
- inappropriate schedule of product administration88
- maternal exposure during pregnancy82
- drug ineffective80
- multiple sclerosis80
- off label use80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 10 |
| 2019 | 1 |
| 2021 | 48 |
| 2022 | 26 |
| 2023 | 247 |
| 2024 | 1,012 |
| 2025 | 1,783 |
| 2026 | 760 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,265 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 1,435 | 119.5 | 114.6 | 165,375 |
| multiple sclerosisSignal | 80 | 9.1 | 7.3 | 565 |
| multiple sclerosis relapseSignal | 99 | 7.8 | 6.4 | 582 |
| illnessSignal | 100 | 5.2 | 4.3 | 341 |
| maternal exposure during pregnancySignal | 82 | 5.0 | 4.0 | 257 |
| urinary tract infectionSignal | 103 | 3.3 | 2.7 | 161 |
| inappropriate schedule of product administrationSignal | 88 | 2.6 | 2.1 | 89 |
| gait disturbanceSignal | 90 | 2.5 | 2.1 | 83 |
| fatigue | 238 | 1.7 | 1.5 | 63 |
| malaise | 116 | 1.4 | 1.2 | 15 |
| asthenia | 94 | 1.4 | 1.1 | 8 |
| headache | 124 | 1.1 | 0.9 | 0 |
| pain | 109 | 1.0 | 0.8 | 0 |
| off label use | 80 | 0.5 | 0.4 | 43 |
| drug ineffective | 80 | 0.3 | 0.3 | 117 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.